In addition, the monophosphoryl lipid A, a TLR4 agonist, was approved by the Food and Drug Administration [103] and showed that metastatic macrophages can be reprogrammed to kill cancer cells in a murine model of luminal B breast cancer when administered intratumorally or intraperitoneally jointly with IFNγ. The gene discussed is TLR4; the disease is cancer.